Orion Corporation: Managers’ transactions – Agendum Oy
November 16 2023 - 3:15AM
Orion Corporation: Managers’ transactions – Agendum Oy
ORION CORPORATION MANAGERS’ TRANSACTIONS 16 NOVEMBER 2023 at
10.15 EET
Orion Corporation: Managers’ transactions – Agendum
Oy
Orion Corporation has received the following disclosure under
Market Abuse Regulation (EU) No 596/2014, regarding transactions
with shares and linked securities in Orion Corporation made by
managers and their closely associated persons.
Orion Oyj - Managers'
Transactions____________________________________________Person
subject to the notification requirementName: Agendum OyPosition:
Closely associated person(X) Legal person (1):Person Discharging
Managerial Responsibilities In IssuerName: Mikael
SilvennoinenPosition: Member of the BoardIssuer: Orion OyjLEI:
74370029VAHCXDR7B745Notification type: INITIAL
NOTIFICATIONReference number: 43741/5/6
____________________________________________Transaction date:
2023-11-15Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type:
SHAREISIN: FI0009014377Nature of transaction: ACQUISITION
Transaction details(1): Volume: 56 Unit price: 37.6 EUR (2):
Volume: 100 Unit price: 37.6 EUR (3): Volume: 563 Unit price: 37.6
EUR
Aggregated transactions (3): Volume: 719 Volume weighted average
price: 37.6
EUR____________________________________________Transaction date:
2023-11-15Venue: CEUXInstrument type: SHAREISIN: FI0009014377Nature
of transaction: ACQUISITION
Transaction details(1): Volume: 73 Unit price: 37.6 EUR (2):
Volume: 586 Unit price: 37.6 EUR (3): Volume: 100 Unit price: 37.6
EUR (4): Volume: 400 Unit price: 37.6 EUR (5): Volume: 32 Unit
price: 37.6 EUR
Aggregated transactions (5): Volume: 1191 Volume weighted
average price: 37.6 EUR
Orion Corporation
Liisa
HurmePresident and CEO |
|
Olli HuotariSVP,
Corporate Functions |
|
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and self-care products. The core therapy areas of our
pharmaceutical R&D are oncology and pain. Proprietary products
developed by Orion are used to treat cancer, neurological diseases
and respiratory diseases, among others. Orion's net sales in 2022
amounted to EUR 1,341 million and the company had about 3,500
employees at the end of the year. Orion's A and B shares are listed
on Nasdaq Helsinki.
Orion (BIT:1ORNBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Orion (BIT:1ORNBV)
Historical Stock Chart
From Sep 2023 to Sep 2024